MX2022004283A - Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo. - Google Patents

Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo.

Info

Publication number
MX2022004283A
MX2022004283A MX2022004283A MX2022004283A MX2022004283A MX 2022004283 A MX2022004283 A MX 2022004283A MX 2022004283 A MX2022004283 A MX 2022004283A MX 2022004283 A MX2022004283 A MX 2022004283A MX 2022004283 A MX2022004283 A MX 2022004283A
Authority
MX
Mexico
Prior art keywords
oxetan
pent
pyrazolo
piperidine
phenoxy
Prior art date
Application number
MX2022004283A
Other languages
English (en)
Spanish (es)
Inventor
Ann Neale
Dolca Thomas
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of MX2022004283A publication Critical patent/MX2022004283A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022004283A 2019-10-09 2020-10-08 Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo. MX2022004283A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913029P 2019-10-09 2019-10-09
US201962942877P 2019-12-03 2019-12-03
PCT/US2020/054809 WO2021072095A1 (en) 2019-10-09 2020-10-08 Methods of treating pemphigus by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Publications (1)

Publication Number Publication Date
MX2022004283A true MX2022004283A (es) 2022-07-12

Family

ID=73030241

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004283A MX2022004283A (es) 2019-10-09 2020-10-08 Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo.

Country Status (12)

Country Link
US (2) US20210106583A1 (https=)
EP (1) EP4041240A1 (https=)
JP (2) JP7784995B2 (https=)
KR (1) KR20220079909A (https=)
CN (1) CN115190798A (https=)
AU (1) AU2020363873A1 (https=)
BR (1) BR112022005575A2 (https=)
CA (1) CA3153750A1 (https=)
CO (1) CO2022005949A2 (https=)
IL (1) IL291726A (https=)
MX (1) MX2022004283A (https=)
WO (1) WO2021072095A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202535403A (zh) * 2023-10-25 2025-09-16 美商普林斯匹亞生物製藥公司 藉由投予（ｒ）－２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧雜環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈治療慢性自發性蕁麻疹

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03455B (me) 2012-09-10 2020-01-20 Principia Biopharma Inc Jedinjenja pirazolopirimidina kao inhibitori kinaze
PT3107544T (pt) 2014-02-21 2021-01-05 Principia Biopharma Inc Sais e forma sólida de um inibidor de btk
US10485797B2 (en) 2014-12-18 2019-11-26 Principia Biopharma Inc. Treatment of pemphigus
CA2971109C (en) 2014-12-24 2024-07-02 Principia Biopharma Inc. SITE-SPECIFIC DOSAGE OF A BTK INHIBITOR
MA45547A (fr) 2016-06-29 2019-05-08 Principia Biopharma Inc Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile
WO2019208805A1 (ja) * 2018-04-27 2019-10-31 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤

Also Published As

Publication number Publication date
JP2025157438A (ja) 2025-10-15
BR112022005575A2 (pt) 2022-06-21
IL291726A (en) 2022-05-01
JP2022552199A (ja) 2022-12-15
WO2021072095A1 (en) 2021-04-15
CA3153750A1 (en) 2021-04-15
US20230158033A1 (en) 2023-05-25
EP4041240A1 (en) 2022-08-17
KR20220079909A (ko) 2022-06-14
TW202128172A (zh) 2021-08-01
AU2020363873A1 (en) 2022-04-14
US20210106583A1 (en) 2021-04-15
JP7784995B2 (ja) 2025-12-12
CN115190798A (zh) 2022-10-14
CO2022005949A2 (es) 2022-07-29

Similar Documents

Publication Publication Date Title
JOP20220130B1 (ar) مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
ZA202204929B (en) Rimegepant for cgrp related disorders
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
MX2021007592A (es) Compuestos macrociclicos y su uso en el tratamiento de enfermedades.
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
CY1125488T1 (el) Παραγωγα πυριδινης και θεραπευτικες χρησεις αυτων ως αναστολεις trpc6
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA038635B9 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
CO2022006087A2 (es) Métodos para el tratamiento de la trombocitopenia inmunitaria mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
MY199779A (en) Pyrrolopyrimidine compound and use thereof
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
WO2021090070A3 (en) Metered dose for disorders in or around the eye
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
MX2022004283A (es) Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo.